Medicines: Enasidenib

0:01:19

The next steps for the IDH2 inhibitor drug enasidenib

0:01:18

Beat AML Master sub-study: enasidenib and response-driven addition of azacitidine in IDH2m AML

0:04:20

Enasidenib’s Role in IDH-Mutant Acute Myeloid Leukemia

0:03:05

Rationale for Enasidenib in AML

0:01:51

Which R/R AML subgroups would benefit from enasidenib treatment?

0:05:52

Eytan M. Stein, MD: Enasidenib Shows 'Encouraging' Efficacy in IDH2-Mutated AML

0:00:50

Combining Azacitadine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML

0:02:11

Advantages of Oral Enasidenib in IDH2-Mutated AML

0:04:05

Enasidenib in Relapsed/Refractory Mutant IDH2 AML

0:03:16

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

0:02:01

Phase II trial of enasidenib in IDH2-mutant MDS

0:02:39

Managing Treatment for IDH2-Mutated AML

0:08:55

AML: Identifying Practical Concerns With Enasidenib

0:04:02

Enasidenib in mIDH relapsed and refractory AML

0:01:24

Phase I Results for Enasidenib in AML

0:02:25

Beat AML: promising results with enasidenib for AML in the frontline

0:02:49

AML post-transplant maintenance: enasidenib & ivosidenib

0:04:24

The efficacy and safety of enasidenib plus azacitidine versus azacitidine monotherapy in mutant-...

0:00:58

Dr. Al-Kali on FDA Approval of Enasidenib in AML

0:05:40

Toxicity Management in the Treatment of R/R AML

0:05:29

Case 3: IDH Inhibitors for the Treatment of AML

0:01:32

IDH inhibitors for AML and MDS

0:01:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

0:07:20

Treating patients with Enasidenib or Ivosidenib: Managing IDH-DS & other Clinical Pearls